Page 5 - Initiate Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Kala Pharmaceuticals Reports Third Quarter 2022 Financial

Planning to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data Expected in 1Q 2024 Ended.

United statesMarjan faridMark iwickiSevere ocular surface disease centerUniversity of california irvineGavin herbert eye instituteDrug administrationKala pharmaceuticals incAlcon incInitiate phasePersistent corneal epithelial defectTopline data expectedFunding operationsChief executive officerRecent business highlightsStage pipeline

Form 8-K Keros Therapeutics, Inc For: Aug 04

Form 8-K Keros Therapeutics, Inc For: Aug 04
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJennifer lacheyJasbir seehraInternational prognostic scoringKeros therapeutics incK keros therapeutics incExchange commissionSecurities exchangeNasdaq stock marketMds foundationSafety review committeeSecurities exchange actZip codeSecurities actExchange actCertain officers

Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Priva

Combined Company Will Operate as Syros Pharmaceuticals and Continue to Advance Syros’ Ongoing Clinical ProgramsSyros Expects to Have Cash Into 2025; At Least a Year Past SELECT-MDS-1 Pivotal DataNow Planning to Initiate Phase 3 Clinical Trial of SY-2101 in APL 2H 2023Syros to Host Conference Call at 8:30 AM ET Today.

United statesUnited kingdomCity ofConley cheeKristin stephensLisam wilsonCourtney solbergHannah deresiewiczEric olsonJason haasDavida rothNancy simonianRichie cunninghamBain capital life sciencesStern investor relations incSyros pharmaceuticals

Hillstream BioPharma (HILS) Provides Corporate Update

Hillstream BioPharma (HILS) Provides Corporate Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Ashok kumarRandy milbyNational centerWorld orphan drug congress united statesUniversity of massachusetts chan medical schoolTranslational sciencesInvestment communityIndian institute of technology delhiDana farber cancer instituteHillstream biopharma incWall streetChief executiveDrug designationUveal melanomaOrphan drug designationRare pediatric disease designation

Hillstream BioPharma Provides Corporate Update

Recent milestones include FDA Orphan Drug Designations for HSB-1216 and HSB-888 World-class scientific advisory team and growing and distinguished patent.

South australiaAshok kumarRandy milbyNational centerWorld orphan drug congress united statesUniversity of massachusetts chan medical schoolTranslational sciencesExchange commissionInvestment communityIndian institute of technology delhiDana farber cancer instituteHillstream biopharma incDrug designationsChief executiveDrug designationUveal melanoma